NCT06211790 2024-01-18
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
Phase 2 Recruiting
Clinical Trials
11 trialsNCT01185366 2021-04-28
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02504892 2019-03-22
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02479490 2018-01-16
PREV
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT00331409 2017-10-26
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00651482 2017-04-11
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Stanford University
Phase 2 Terminated
NCT00903175 2016-11-08
RECORD-3
Novartis
Phase 2 Completed
NCT00831480 2016-03-21
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
Baylor College of Medicine
Phase 2 Terminated
NCT00446368 2016-03-17
RAD001
The Methodist Hospital Research Institute
Phase 2 Completed
NCT01888042 2016-02-10
POORTOR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT00323739 2013-07-26
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed